All In Biotech

Drug Trial Radar · NCT04992208

Safety of an Inactivated SARS-CoV-2 Vaccine for Prevention of COVID-19 in Children and Adolescents

Safety Observation of the Inactivated SARS-CoV-2 Vaccine (Vero Cell) in Population Aged 3~17 Years : A Multicenter,Open-label Study

Last checked: Nov 20, 2026Latest source record: Sep 25, 2023 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

31,041

Actual

Start

Jul 24, 2021

Primary completion

Mar 24, 2023

Study completion Aug 31, 2023

Sponsor

Sponsor type
Industry
First posted
Aug 5, 2021

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Prevention
FDA-regulated drug
No
Who can join
All sexes, from 3 years, up to 17 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

This study is a multi-center and open design, phase Ⅳ clinical trial of an inactivated SARS-CoV-2 vaccine (CoronaVac) manufactured by Sinovac Research and Development Co., Ltd.The purpose of this study is to evaluate the safety of the SARS-CoV-2 Inactivated vaccine in population aged 3\~17 years and in people with pre-existing disease to provide reference for improving the immunization strategy of COVID-19 vaccine.

Conditions

  • COVID-19

Interventions

  • Experimental GroupBiological

    SARS-CoV-2 Inactivated Vaccine 600SU inactivated virus in 0·5 mL of aluminium hydroxide solution per injection

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Safety index 1-incidence of adverse reactionsTime frame: Within 0~7 days after each dose

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Yongping Center for Diseases Control and Prevention

    Dali, Yunnan, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.